
**PROFIT GUIDANCE FOR THE GROUP'S UNAUDITED FINANCIAL RESULTS
FOR FOURTH QUARTER AND FINANCIAL YEAR ENDED 31 DECEMBER 2016**

The Board of Directors (the "**Board**") of Pharmesis International Ltd. (the "Company", together with its subsidiaries, collectively the "Group") wishes to announce that after preliminary assessment of the Group's unaudited financial results, the Board would like to inform the shareholders and investors that the Group is expected to report a net loss for the unaudited financial results for the fourth quarter ("**4QFY16**") and financial year ended 31 December 2016 ("**FY2016**").

The expected net loss was mainly attributed to lower revenue from prescribed drug segment and impairment of its assets.

Further details of the Group's financial performance will be disclosed when the Company announces its unaudited financial results for 4QFY16 and FY2016 on 28 February 2017.

The Board wishes to advise its shareholders and investors to exercise caution when dealing with the shares of the Company. Shareholders and investors should consult with their stock brokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions that they should take.

BY ORDER OF THE BOARD

Jiang Yun
Executive Director and Chief Executive Officer
21 February 2017